Filing Details
- Accession Number:
- 0001393905-18-000021
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-01-24 19:01:23
- Reporting Period:
- 2018-01-19
- Accepted Time:
- 2018-01-24 19:01:23
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1689813 | Biohaven Pharmaceutical Holding Co Ltd. | BHVN | Crude Petroleum & Natural Gas (1311) | A6 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1095435 | Portage Biotech Inc. | 47 Avenue Road Suite 200 Toronto A6 M5R 2G3 | No | No | No | Yes |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2018-01-19 | 35,119 | $30.03 | 78,771 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-01-23 | 24,277 | $331,520.00 | 54,494 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2017.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 - $30.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 - $33.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- The reduction in shares reflects the sale of shares reported upon and the dividend distribution of 6,102,729 shares of common stock completed on January 16, 2018.
Billionaire Hedge Funds
